

L Number	Hits	Search Text	DB	Time stamp
1	3076	knockout and promoter and operably	USPAT; US-PGPUB	2003/06/04 08:02
2	3020	(knockout and promoter and operably) and (operably adj linked)	USPAT; US-PGPUB	2003/06/04 08:02
3	2913	((knockout and promoter and operably) and (operably adj linked)) and mouse	USPAT; US-PGPUB	2003/06/04 08:02
4	6	((((knockout and promoter and operably) and (operably adj linked)) and mouse) and (promoter adj fusion)	USPAT; US-PGPUB	2003/06/04 08:03

FILE 'MEDLINE, BIOSIS, EMBASE, LIFESCI, CAPLUS' ENTERED AT 06:39:57 ON 04
JUN 2003

L1	2 S RAMP1 AND KNOCKOUT
L2	2 DUP REM L1 (0 DUPLICATES REMOVED)
L3	60 S RAMP1 AND TRANSMEMBRANE
L4	22 DUP REM L3 (38 DUPLICATES REMOVED)
L5	1 S RAMP1 AND DEFICIENT
L6	231 S RAMP1 AND CELL
L7	19 S L6 AND RECOMBINANT
L8	13 DUP REM L7 (6 DUPLICATES REMOVED)

L Number	Hits	Search Text	DB	Time stamp
2	6	RAMP1 and transmembrane	USPAT; US-PGPUB; DERWENT	2003/06/04 06:53
1	31	RAMP1	USPAT; US-PGPUB; DERWENT	2003/06/04 07:07

8 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2003 ACS

AN 2003:261950 CAPLUS

DN 138:282345

TI Humanized calcitonin gene-related peptide (CGRP) receptor comprising calcitonin-receptor-like receptor (CRLR) and the receptor-activity-modifying protein 1 (**RAMP1**)

IN Kane, Stefanie A.; Salvatore, Christopher A.; Mallee, John J.; Koblan, Kenneth S.; Oliver, Kevin R.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003027252	A2	20030403	WO 2002-US30501	20020926
	W: CA, JP, US				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
PRAI	US 2001-325295P	P	20010927		

AB The invention provides method for creating a humanized version of a calcitonin gene-related peptide (CGRP) receptor, which comprises the G-protein coupled receptor calcitonin-receptor-like receptor (CRLR) and the receptor-activity-modifying protein 1 (**RAMP1**). The humanized CGRP receptors of the present invention attain pharmacol. profiles similar to the wild type human receptor via modifications to the resp. mammalian **RAMP1** nucleotide sequence, specifically at amino acid 74. Also described are related **recombinant** vectors, **recombinant** hosts and assocd. methods for generating such humanized CGRP receptors. Also presented are non-human transgenic animals which express humanized **RAMP1**. Such animals have been engineered to provide for a CGRP pharmacol. profile similar to human CGRP. Antagonist of CGRP function may be useful in the treatment of various disorders such as migraine headaches, pain indications, menopausal hot flashes, migraine prophylaxis, chronic tension type headache, cluster headache, neurogenic or chronic inflammation, gastrointestinal disorders, type 2 diabetes and cardiovascular disorders.